A carregar...
Challenges of driving CD30-directed CAR-T cells to the clinic
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. CD3...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6404322/ https://ncbi.nlm.nih.gov/pubmed/30841880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5415-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|